home / stock / pmxsf / pmxsf news
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company is set to undergo a restructure to refocus on developing drugs to treat blood-related cancers. This involves the creation of clinical stage drug development company, Syntara and the sale of its manni...
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips speaks with Proactive after releasing data from a final interim analysis of 10 patients who have completed six months’ treatment with its drug PXS-5505 in an open label phase 2 clinical trial in patients with the bone ma...
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company has made great progress towards commercialisation in a Phase 1C study of its topical Pan LOX inhibitor, achieving a well-tolerated safety profile and a marked change in scar composition. Importantly,...
(NewsDirect) Pharmaxis Ltd (ASX:PXS) CEO Gary Phillips tells Proactive the company will add a combination treatment arm to the current Phase 2 clinical trial of PXS‐5505 in myelofibrosis following helpful feedback from the US FDA. He says they’re already in discussion with the e...
The following slide deck was published by Pharmaxis Ltd in conjunction with this event. For further details see: Pharmaxis (PMXSF) Investor Presentation - Slideshow
Galecto has filed proposed terms for an $85 million U.S. IPO. The firm is development treatments for various fibrosis diseases. GLTO has produced impressive trial results to-date. For life science investors with a long-term hold time frame, the IPO is worth considering. ...
News, Short Squeeze, Breakout and More Instantly...
Pharmaxis Ltd Company Name:
PMXSF Stock Symbol:
OTCMKTS Market:
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company is set to undergo a restructure to refocus on developing drugs to treat blood-related cancers. This involves the creation of clinical stage drug development company, Syntara and the sale of its manni...
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips speaks with Proactive after releasing data from a final interim analysis of 10 patients who have completed six months’ treatment with its drug PXS-5505 in an open label phase 2 clinical trial in patients with the bone ma...
(NewsDirect) Pharmaxis Ltd (ASX:PXS, OTC:PMXSF) CEO Gary Phillips tells Proactive the company has made great progress towards commercialisation in a Phase 1C study of its topical Pan LOX inhibitor, achieving a well-tolerated safety profile and a marked change in scar composition. Importantly,...